Wedbush Boosts Vor Biopharma (NASDAQ:VOR) Price Target to $18.00

Vor Biopharma (NASDAQ:VOR) had its price target lifted by research analysts at Wedbush from $15.00 to $18.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Wedbush’s price target would indicate a potential upside of 19.30% from the company’s current price.

Several other brokerages have also commented on VOR. Wall Street Zen raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Saturday, April 4th. Wells Fargo & Company started coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target on the stock. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. HC Wainwright reduced their target price on Vor Biopharma from $32.00 to $31.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Price Performance

Shares of VOR opened at $15.09 on Thursday. The company has a 50-day moving average of $15.11 and a 200 day moving average of $14.31. Vor Biopharma has a 1-year low of $3.20 and a 1-year high of $65.80. The firm has a market capitalization of $817.56 million, a price-to-earnings ratio of -0.04 and a beta of 1.75.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. On average, equities analysts anticipate that Vor Biopharma will post -3.25 earnings per share for the current fiscal year.

Insider Activity

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the sale, the director owned 4,555,741 shares of the company’s stock, valued at approximately $75,579,743.19. The trade was a 11.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 3,002,903 shares of company stock worth $49,412,176 over the last 90 days. Company insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

Institutional investors have recently modified their holdings of the business. Fcpm Iii Services B.V. purchased a new position in Vor Biopharma during the 3rd quarter valued at about $18,496,000. Independent Financial Group LLC purchased a new position in shares of Vor Biopharma during the first quarter valued at approximately $249,000. Simplify Asset Management Inc. acquired a new stake in Vor Biopharma during the first quarter worth approximately $955,000. Cannon Global Investment Management LLC acquired a new position in Vor Biopharma in the 1st quarter valued at $209,000. Finally, Findell Capital Management LLC purchased a new position in shares of Vor Biopharma during the 4th quarter worth $3,021,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).